Global Post-traumatic Stress Disorder Treatment Market, by Drug Class (Antidepressants, Anti-anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta-Blockers, and Others (Benzodiazepines and Others)), by Route of Administration (Oral, Parenteral, and Nasal), by Age Group (Pediatric, Adult, and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) wasestimated to be valued at US$ 1034.3 Million in 2022 and is projected to exhibit a CAGR of 5.1% over the forecast period (2022 – 2030).
The increasing number of PTSD (Post-Traumatic Stress Disorder) suffering adults and teenagers globally is expected to drive the growth of the global Post-traumatic Stress treatment market over the forecast period. For instance, according to the U.S. Department of Veterans Affairs, U.S. Government Department, about 12 million adults who have gone through trauma suffer from PTSD every year. About 8% of women are found to develop PTSD sometime in their life whereas around 4% of men suffer from PTSD in the U.S. every year.
Furthermore, an increasing number of organic strategies, such as company expansion or the launch of a new subsidiary by the market players is expected to boost the growth of the global post-traumatic stress disorder treatment market. For instance, in August 2020, ATAI Life Sciences, a biotechnology company, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of 3, 4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications. This launch of a new subsidiary by ATAI Life Sciences will further help the company to expand its product portfolio in the treatment of post-traumatic stress disorder (PTSD) and strengthen its position in the market.
Global Post-traumatic Stress Disorder Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
The increasing number of cases of PTSD during the covid-19 pandemic increased the growth of the global post-traumatic stress disorder treatment market. For instance, in February 2021, according to a report published by JAMA Psychiatry, a Peer-reviewed journal, reported that in 2020, Post-traumatic stress disorder prevalence was 30.2% after acute COVID-19 infection in the U.S., which is in line with findings in survivors of previous coronavirus illnesses
Thus, increasing cases of PTSD during the COVID-19 pandemic is expected to drive the global post-traumatic stress disorder treatment market growth over the forecast period.
Global Post-traumatic Stress Disorder Treatment Market: Key Developments
In November 2021, COMPASS Pathways plc, a pharmaceutical company, announced the initiation of a phase 2 clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder (PTSD). The launch of this study by COMPASS Pathways plc will further expand its research pipeline in psilocybin therapy with COMP360.
In September 2021, Royal Medical Benevolent Fund, a non-profit organization, was awarded US$ 28,310 by British Medical Association, a registered trade union for doctors in the U.K., to help support doctors facing post-traumatic stress disorder (PTSD) and moral injury as a result of the Covid-19 pandemic, where nearly 40% of ICU (Intensive Care Unit) and anesthetic staff reported symptoms consistent with a probable diagnosis of PTSD (Post-traumatic Stress Disorder).
Browse 36 Market Data Tables and 25 Figures spread through 176 Pages and in-depth TOC on " Global Post-traumatic Stress Disorder Treatment Market, by Drug Class (Antidepressants, Anti-anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta-Blockers, and Others (Benzodiazepines and Others)), by Route of Administration (Oral, Parenteral, and Nasal), by Age Group (Pediatric, Adult, and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global Forecast to 2030"
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Post-traumatic Stress Disorder Treatment Market:
- Global Post-traumatic Stress Disorder Treatment Market is expected to expand at a CAGR of 5.1% during the forecast period (2022–2030), owing to the increasing number of research and development by the key market players in the treatment of post-traumatic stress disorder. For instance, on September 23, 2022, BioNTech SE, a biotechnology company, in collaboration with Pfizer, a pharmaceutical company, announced the initiation of the clinical trial to evaluate the safety, the extent of the side effects, and immune responses of the vaccine (called bivalent BNT162b2 Omicron containing vaccine) in healthy children and is actively recruiting for phase 3.
- Among drug class, the antidepressant segment is expected to hold the dominant position in 2022, as U.S. FDA (Food and Drug Administration) approved SSRIs (Selective Serotonin Reuptake Inhibitors) such as Zoloft (sertraline) and Paxil (paroxetine) for the treatment of PTSD and is recommended as the first line of treatment for PTSD
- Among Route of Administration, oral segment is expected to hold the dominant position, owing to increasing research and development in PTSD treatment by the market players. For instance, on April 6, 2022, Charite University, Berlin, Germany, an University Hospital, in collaboration with the German Federal Ministry of Education and Research, a Government Ministry of Europe, initiated a clinical trial for Treating Nightmares in Post-traumatic Stress Disorder with oral Clonidine (antihypertensives) and Doxazosin (alpha-blockers) and is currently recruiting for phase 2.
- Major players operating in the global post-traumatic stress disorder treatment market include Jazz Pharmaceuticals plc., Madrigal Mental Care, Allergan PLC, Otsuka Pharmaceutical Co., Ltd., apex laboratories Pvt. Ltd., H. Lundbeck A/S (Lundbeck), Neurovation Labs, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc., Aurobindo Inc., Amneal Pharmaceuticals LLC, Teva Pharmaceuticals Industries Ltd., and Mylan Pharmaceuticals (Viatris Inc.)
